A detailed history of Susquehanna International Group, LLP transactions in Caribou Biosciences, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 63,550 shares of CRBU stock, worth $123,922. This represents 0.0% of its overall portfolio holdings.

Number of Shares
63,550
Previous 99,954 36.42%
Holding current value
$123,922
Previous $513,000 79.73%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 15, 2024

SELL
$1.62 - $5.05 $58,974 - $183,840
-36,404 Reduced 36.42%
63,550 $104,000
Q1 2024

May 07, 2024

SELL
$4.82 - $8.26 $85,082 - $145,805
-17,652 Reduced 15.01%
99,954 $513,000
Q4 2023

Feb 14, 2024

SELL
$3.58 - $6.25 $152,980 - $267,075
-42,732 Reduced 26.65%
117,606 $673,000
Q3 2023

Nov 14, 2023

BUY
$4.08 - $8.14 $134,709 - $268,758
33,017 Added 25.93%
160,338 $766,000
Q2 2023

Aug 11, 2023

SELL
$4.04 - $5.47 $6,504 - $8,806
-1,610 Reduced 1.25%
127,321 $541,000
Q1 2023

May 16, 2023

BUY
$4.3 - $7.78 $477,897 - $864,661
111,139 Added 624.66%
128,931 $684,000
Q4 2022

Feb 14, 2023

SELL
$5.57 - $11.01 $199,417 - $394,180
-35,802 Reduced 66.8%
17,792 $111,000
Q3 2022

Nov 14, 2022

BUY
$5.34 - $12.79 $231,403 - $554,241
43,334 Added 422.36%
53,594 $565,000
Q2 2022

Aug 15, 2022

SELL
$5.1 - $9.74 $76,347 - $145,807
-14,970 Reduced 59.33%
10,260 $56,000
Q1 2022

May 16, 2022

BUY
$8.42 - $15.32 $90,658 - $164,950
10,767 Added 74.45%
25,230 $232,000
Q4 2021

Feb 14, 2022

BUY
$14.59 - $23.26 $211,015 - $336,409
14,463 New
14,463 $218,000

Others Institutions Holding CRBU

About Caribou Biosciences, Inc.


  • Ticker CRBU
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,840,800
  • Market Cap $119M
  • Description
  • Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1...
More about CRBU
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.